# Protocol Operations Auditor Packet Design

## Goal

Describe a future internal-only Protocol Operations Auditor Packet that can bundle the existing offline verification artifacts without introducing a public product surface, runtime behavior, or launch commitment.

## Scope

This design covers PR #157 only.

In scope:

- An internal design note for a future Protocol Operations Auditor Packet.
- A restrained description of the packet contents and intended verification posture.
- Explicit proof boundaries for what the packet can and cannot establish.
- Limited commercialization notes that preserve BioStack's educational and observational boundary.

Out of scope:

- API routes
- Frontend work
- Public website copy
- Billing implementation
- PDF generation
- Sample health data
- Marketing claims
- Database or runtime behavior changes

## Packet Intent

The future Protocol Operations Auditor Packet is intended to package already-existing offline verification artifacts into a handoff-friendly internal trust pack for auditors, reviewers, or compliance-facing operators. The packet is a packaging concept around deterministic local artifacts. It is not a new verification engine, medical product claim, or runtime BioStack surface.

The packet should remain backend/docs only, offline-verifiable, and additive to the current verifier chain.

## Intended Contents

The packet should be defined as a collection of local artifacts and supporting notes:

- Protocol Operations export bundle JSON
- verification receipt JSON
- offline verifier CLI
- machine-readable CLI result JSON
- contract snapshots
- release checklist
- verification walkthrough
- failure-mode guide
- boundary statement

Each item should be treated as supplied verification material. The packet should not depend on live API access, hosted services, database reads, or runtime user surfaces.

## What The Packet Proves

When assembled from the supported offline artifacts and verified with the existing CLI, the packet is intended to prove only the following bounded claims:

- supplied bundle structure is intact
- embedded hashes recompute deterministically
- receipt binds to captured verification material
- receipt identity/hash recomputes deterministically
- CLI can verify artifacts offline

These proofs are mechanical and artifact-bound. They describe deterministic verification of supplied files, not clinical truth or runtime truth.

## What The Packet Does Not Prove

The packet must explicitly avoid overstating what offline verification can establish. It does not prove:

- clinical correctness
- treatment validity
- dosing appropriateness
- medical safety
- PDF authenticity
- database state
- runtime execution behavior
- user identity
- provider approval

The packet also must not imply diagnosis, treatment, prescription, medical endorsement, or any claim that a hosted BioStack environment executed correctly.

## Assembly Posture

The future packet should be assembled from frozen local artifacts that already exist in the offline verification chain. The packaging posture should stay deterministic and conservative:

- Prefer checked-in or emitted artifacts over generated presentation layers.
- Keep verification steps local-file-only.
- Preserve receipt-only verification when only a receipt artifact is available.
- Keep contract snapshots and boundary language aligned with the verifier and release checklist.
- Avoid adding packet-specific logic that widens the CLI into export generation, persistence inspection, or runtime analysis.

## Documentation Components

The packet should eventually be accompanied by lightweight internal documentation that helps an auditor or operator understand how to evaluate the supplied materials:

- A verification walkthrough that shows the intended offline verification order.
- A failure-mode guide that explains hash mismatch, schema drift, invalid receipt, and boundary-language failure conditions.
- A boundary statement that repeats the educational, observational, non-clinical posture of the verifier chain.

These notes should remain internal and procedural. They should explain how to inspect the packet, not market it.

## Restrained Future Commercialization

If BioStack later commercializes this lane, the framing should remain narrow and non-public until explicitly approved. Possible future directions may include:

- possible paid trust-pack export
- possible auditor-facing verification bundle
- possible enterprise compliance add-on

This design does not define pricing, public claims, packaging promises, launch timing, or a commitment to ship any commercialization surface.

## Guardrails

Any future implementation that follows this note should preserve the current offline verification boundaries:

- no API route
- no frontend
- no public website copy
- no billing
- no PDF generation
- no sample health data
- no marketing exaggeration

If future work needs broader product behavior, it should start with a separate directive rather than expanding this design note in place.

## Validation

Run:

```bash
dotnet build backend/BioStack.sln
dotnet test backend/tests/BioStack.Application.Tests/BioStack.Application.Tests.csproj --filter ProtocolIntelligenceOfflineBoundaryTests
git diff --check origin/main...HEAD
```

## Self-Review

- The note stays internal, backend/docs only, and future-facing.
- The proof language is deterministic and artifact-bound.
- The non-proof list preserves BioStack's educational and observational boundary.
- The commercialization section is intentionally restrained and non-committal.
